In the past 15 years, enormous progress has been made in the prevention and treatment of metastatic melanoma due to the development of BRAF and MEK inhibitors for BRAF V600-mutated melanoma, and even more importantly, immune checkpoint inhibitors (ICIs) [4,5]. The gene discussed is BRAF; the disease is melanoma.